• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis.

作者信息

Wixner Jonas, Pilebro Björn, Lundgren Hans-Erik, Olsson Malin, Anan Intissar

机构信息

a Department of Public Health and Clinical Medicine , Umeå University , Umeå , Sweden.

出版信息

Amyloid. 2017 Mar;24(sup1):78-79. doi: 10.1080/13506129.2016.1269739. Epub 2016 Dec 31.

DOI:10.1080/13506129.2016.1269739
PMID:28042702
Abstract
摘要

相似文献

1
Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis.强力霉素和熊去氧胆酸对转甲状腺素蛋白淀粉样变性的影响。
Amyloid. 2017 Mar;24(sup1):78-79. doi: 10.1080/13506129.2016.1269739. Epub 2016 Dec 31.
2
Doxycycline-tauroursodeoxycholic acid treatment: effects in the heart of a transthyretin V30M transgenic mouse model.强力霉素-牛磺熊去氧胆酸治疗：在转甲状腺素蛋白V30M转基因小鼠模型心脏中的作用
Amyloid. 2017 Mar;24(sup1):80. doi: 10.1080/13506129.2016.1277695.
3
Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.转甲状腺素蛋白（ATTR）淀粉样变性肾病：来自一种转甲状腺素蛋白稳定剂分子的经验教训。
Amyloid. 2017 Mar;24(sup1):81-82. doi: 10.1080/13506129.2016.1277697.
4
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.Patisiran，一种 RNA 干扰疗法，对遗传性转甲状腺素蛋白介导的淀粉样变性患者心脏参数的影响。
Circulation. 2019 Jan 22;139(4):431-443. doi: 10.1161/CIRCULATIONAHA.118.035831.
5
Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis.携带缬氨酸30蛋氨酸突变型转甲状腺素蛋白淀粉样变性患者队列中的心脏受累情况
Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):92-94. doi: 10.1016/j.rec.2017.11.017. Epub 2017 Dec 7.
6
Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy.他法米地治疗的转甲状腺素蛋白淀粉样心肌病患者心室功能及心脏磁共振成像组织特征的纵向演变
Amyloid. 2024 Jun;31(2):145-147. doi: 10.1080/13506129.2023.2284108. Epub 2023 Dec 9.
7
Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.通过人血浆中亚基交换对转甲状腺素蛋白动力学稳定剂进行盲法效力度比较。
Amyloid. 2021 Mar;28(1):24-29. doi: 10.1080/13506129.2020.1808783. Epub 2020 Aug 18.
8
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.塔非酰胺在转甲状腺素蛋白淀粉样心肌病中的作用：对转甲状腺素蛋白稳定性及临床结局的影响
Circ Heart Fail. 2015 May;8(3):519-26. doi: 10.1161/CIRCHEARTFAILURE.113.000890. Epub 2015 Apr 14.
9
A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G > T, p.Ala140Ser).一例由极其罕见的转甲状腺素蛋白Ala120Ser突变（c.418G > T，p.Ala140Ser）导致的转甲状腺素蛋白淀粉样变性伴肌病、神经病和心肌病病例。
Amyloid. 2018 Sep;25(3):211-212. doi: 10.1080/13506129.2018.1491398. Epub 2018 Jul 24.
10
Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval.特发性肺纤维化患者接受尼达尼布治疗后发生肝损伤的风险：一项真实世界研究
Amyloid. 2024 Sep;31(3):226-231. doi: 10.1080/13506129.2024.2376202. Epub 2024 Jul 17.

引用本文的文献

1
Transthyretin cardiac amyloidosis: advances and ambiguities.转甲状腺素蛋白心脏淀粉样变性：进展与争议
Heart Fail Rev. 2025 Aug 29. doi: 10.1007/s10741-025-10552-9.
2
Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications.转甲状腺素蛋白淀粉样变心肌病的疾病修饰疗法：现有及新兴药物
Pharmacotherapy. 2025 Feb;45(2):124-144. doi: 10.1002/phar.4639. Epub 2024 Dec 23.
3
Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances.心脏淀粉样变的治疗策略进展：从发病机制的发现到诊断和治疗的进步。
Cardiol Clin. 2025 Feb;43(1):93-110. doi: 10.1016/j.ccl.2024.09.006. Epub 2024 Oct 22.
4
Clinical characterization of patients with cardiac amyloidosis in a referral center of Colombia.哥伦比亚转诊中心的心脏淀粉样变性患者的临床特征。
Arch Cardiol Mex. 2024 Aug 1;94(4):451-458. doi: 10.24875/ACM.23000236.
5
Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis.心脏淀粉样变性的治疗现状与未来方向及预后
Ther Clin Risk Manag. 2023 Jul 10;19:581-597. doi: 10.2147/TCRM.S414821. eCollection 2023.
6
Cardiac amyloidosis: state-of-the-art review.心脏淀粉样变性：最新综述
J Geriatr Cardiol. 2023 May 28;20(5):361-375. doi: 10.26599/1671-5411.2023.05.006.
7
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials.治疗转甲状腺素蛋白淀粉样变心肌病：临床试验的经验教训
Front Cardiovasc Med. 2023 May 23;10:1154594. doi: 10.3389/fcvm.2023.1154594. eCollection 2023.
8
Emerging Therapies for Transthyretin Amyloidosis.转甲状腺素蛋白淀粉样变性的新兴治疗方法。
Curr Oncol Rep. 2023 Jun;25(6):549-558. doi: 10.1007/s11912-023-01397-2. Epub 2023 Mar 21.
9
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.口服治疗用于治疗转甲状腺素相关淀粉样心肌病。
Int J Mol Sci. 2022 Dec 18;23(24):16145. doi: 10.3390/ijms232416145.
10
Amyloid Disassembly: What Can We Learn from Chaperones?淀粉样蛋白解聚：我们能从伴侣蛋白中学到什么？
Biomedicines. 2022 Dec 17;10(12):3276. doi: 10.3390/biomedicines10123276.